5-HT 3 Receptor Antagonists for Prevention of Late Acute-Onset Emesis

Abstract

Spanish

French

OBJECTIVE

To review the currently available literature on the efficacy of the 5–HT₃ receptor antagonists in the prevention of late acute-onset chemotherapy-induced nausea and vomiting (12–24 h after cytotoxic treatment).

DATA SOURCES

Primary articles were identified by PubMed search (performed in March 2004) and through secondary sources. Search terms included granisetron, ondansetron, tropisetron, dolasetron, acute, chemotherapy, nausea, and vomiting (a further search was performed for palonosetron in March 2004).

STUDY SELECTION AND DATA EXTRACTION

All studies that performed regular assessments (every 2–6 h) of antiemetic control over the first 24 hours with 5–HT₃ receptor antagonists were evaluated.

DATA SYNTHESIS

Current guidelines recommend the use of 5–HT₃ receptor antagonists for the control of chemotherapy-induced nausea and vomiting but do not differentiate between the available agents. However, there is variability in the pharmacokinetic and pharmacodynamic profiles of these agents, and this has implications for dosing regimen, safety, efficacy, and potential drug—drug interactions. Cytotoxic agents vary in the time profile of their emetic effect; this must be considered when choosing an appropriate 5–HT₃ receptor antagonist. The optimal agent should be simple to administer and provide safe and effective antiemetic protection over the whole 24–hour period.

CONCLUSIONS

The differences between the 5-HT₃ receptor antagonists have important consequences for their dosing and efficacy in the control of late acute-onset chemotherapy-induced nausea and vomiting.

Keywords

antiemetics chemotherapy nausea vomiting

Get full access to this article

View all access options for this article.

References

1. Laszlo

Emesis as a limiting toxicity in cancer chemotherapy. In: Laszlo

, ed. Antiemetics and cancer chemotherapy. Baltimore: Williams and Wilkins, 1983:1–5.

2. Roila

Boschetti

Tonato

Basurto

Bracarda

Picciafuoco

Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. Am J Clin Oncol 1991;14:238–42.

3. Aapro

5-HT₃ receptor antagonists: are they all the same? Management of nausea and vomiting: revisiting the role of the 5–HT₃ receptor antagonists. Cancer Today 2002(suppl 1):S1–15.

4. Gralla

Osoba

Kris

Kirkbride

Hesketh

Chinnery

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. An ASCO special article. J Clin Oncol 1999;17:2971–94.

5. Andrews

PLR

Blower

PR.

5–HT₃ receptor antagonists and emesis: a preclinical review. Pharma Medica 1999;13:151–91.

6. Carmichael

Keizer

Cupissol

Milliez

Scheidel

Schindler

AE.

Use of granisetron in patients refractory to previous treatment with antiemetics. Anti-Cancer Drugs 1998;9:381–5.

7. van Wijngaarden

Tulp

Soudijn

The concept of selectivity in 5–HT receptor research. Eur J Pharmacol 1990;138:301–12.

8. Wong

Clark

Leung

Loury

Bonhaus

Jakeman

The interaction of RS 25259–197, a potent and selective antagonist, with 5–HT₃ receptors, in vitro. Br J Pharmacol 1995;114:851–9.

9. Addelman

Erlichman

Fine

Warr

Murray

Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 1990;8: 337–41.

10.

10. Roila

Del Favero

Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 1995;29:95–109.

11.

11. Lippert

Dimmitt

Martin

Cramer

Plezia

Hahne

Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapy. Am J Therapeut 1999;6:129–35.

12.

12. Kees

Farber

Bucher

Mair

Morike

Grobecker

Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Br J Clin Pharmacol 2001;52:705–7.

13.

13. Eisenberg

MacKintosh

Ritch

Cornett

Macciocchi

Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 2004;15:330–7.

14.

14. Cooper

Arnold

BDC

Rapeport

WG.

Inhibition of 5–HT induced axon-reflex flares by BRL 43694, a novel 5–HT₃ receptor antagonist (abstract). Br J Clin Pharmacol 1988;25:106P–7P.

15.

15. Upward

Arnold

BBC

Link

Pierce

Allen

Tasker

TCG.

The clinical pharmacology of granisetron (BRL 43694), a novel specific 5–HT₃ antagonist. Eur J Cancer 1990;26(suppl 1):S12–5.

16.

16. Sweetland

Lettis

Fowler

Thomas

Duration of the inhibitory effect of intravenous ondansetron on intradermal 5–HT—induced flare (abstract). Br J Clin Pharmacol 1992;33:565P.

17.

17. Newberry

Watkins

Sprosen

Blackburn

Grahame-Smith

Leslie

RA.

BRL 46470 potently antagonizes neural responses activated by 5–HT₃ receptors. Neuropharmacol 1993;32:729–35.

18.

18. Wolf

Preclinical and clinical pharmacology of the 5–HT₃ receptor antagonists. Scand J Rheumatol 2000;29(suppl 113):37–45.

19.

19. Blower

PR.

A pharmacologic profile of oral granisetron (Kytril tablets). Semin Oncol 1995;4(suppl 10):3–5.

20.

20. Gebauer

Merger

Kilbinger

Modulation by 5–HT₃ and 5–HT₄ receptors of the release of 5–hydroxytryptamine from the guinea-pig small intestine. Naunyn Schmiedebergs Arch Pharmacol 1993;347:137–40.

21.

21. Carmichael

Cantwell

BMJ

Edwards

Zussman

Thompson

Rapeport

A pharmacokinetic study of granisetron (BRL 43694A), a selective 5–HT₃ receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 1989;24:45–9.

22.

22. Cupissol

Serrou

Caubel

The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer 1990;26(suppl 1):S23–7.

23.

23. Perez

Navari

Kaplan

Gralla

Grunberg

Palmer

Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer 1997;5: 31–7.

24.

24. Navari

Kaplan

Gralla

Grunberg

Palmer

Fitts

Efficacy and safety of granisetron, a selective 5–hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994;12:2204–10.

25.

25. Tsuchida

Hayashi

Asami

Yamamoto

Yokoyama

Mugishima

Effects of granisetron in children undergoing high-dose chemotherapy: a multi-institutional, cross-over study. Int J Oncol 1999;14: 673–9.

26.

26. Heron

Goedhals

Jordaan

Cunningham

Cedar

Oral granisetron alone and in combination with dexamethasone: a double-blind randomised comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol 1994;5:579–84.

27.

27. Kleisbauer

Garcia-Giron

Antimi

Azevedo

Balmes

Masuti-Sureda

Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis. Anticancer Drugs 1998;9:387–92.

28.

28. Audhuy

Cappelaere

Martin

Cervantes

Fabbro

Riviere

A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996;32A:807–13.

29.

29. Harman

Omura

Ryan

Hainsworth

Cramer

Hahne

WF.

A randomised, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol 1996;38:323–8.

30.

30. Yielding

Bertoli

Eisenberg

Plezia

Modiano

Alberts

Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. Am J Clin Oncol 1996;19:619–23.

31.

31. Krzakowski

Graham

Goedhals

Joly

Pawlicki

Rapoport

A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Anticancer Drugs 1998;9:593–8.

32.

32. Cocquyt

Van Belle

Reinhardt

Decramer

MLA

O'Brien

Schellens

JHM.

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001;37:835–42.

33.

33. Park

Rha

Yoo

Kim

Roh

Min

A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. Am J Clin Oncol 1997;20:569–72.

34.

34. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995;6:805–10.

35.

35. Herrington

Kwan

Young

Lagow

Lagrone

Riggs

MW.

Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy. Pharmacotherapy 2000;20:1318–23.

36.

36. Eisenberg

Figueroa-Vadillo

Zamora

Charu

Hajdenberg

Cartmell

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5–HT₃ receptor antagonist: results of a Phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473–82.

37.

37. Gralla

Lichinitser

Van De Vegt

Sleeboom

Mezger

Peschel

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570–7.

38.

38. Hesketh

Navari

Grote

Gralla

Hainsworth

Kris

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996;14:2242–9.

39.

39. Prescribing information. Anzemet (dolasetron mesylate). Kansas City, MO: Aventis Pharmaceuticals, October 2003.

40.

40. Fauser

Duclos

Chemaissani

Del Favero

Cognetti

Diaz-Rubio

Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer 1996;32A:1523–9.

41.

41. Rubenstein

Gralla

Hainsworth

Hesketh

Grote

Modiano

Randomized, double blind, dose—response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose—Response Study Group. Cancer 1997;79:1216–9.

42.

42. Bubalo

Seelig

Karbowicz

Maziarz

RT.

Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001;7:439–45.

43.

43. Terrey

J-P

Aapro

MS.

The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res 1996;8:281–8.

44.

44. de Wit

de Boer

vd Linden

GHM

Stoter

Sparreboom

Verweij

Effective cross-over to granisetron after failure of ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer 2001;85:1099–101.

45.

45. Chua

DTT

Sham

JST

Kwong

DLW

Kwok

CCH

Yue

Foo

Comparative efficacy of three 5–HT₃ antagonists (granisetron, ondansetron and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis. A randomized crossover study. Am J Clin Oncol 2000;23:185–91.

46.

46. Perez

Hesketh

Sandbach

Reeves

Chawla

Markman

Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 1998;16:754–60.

47.

47. Lofters

Pater

Zee

Dempsey

Walde

Moquin

J-P

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997;15:2966–73.

48.

48. Product information. Navoban (tropisetron). New South Wales, Australia: Novartis Pharmaceuticals, October 1997.

49.

49. Prescribing information. Aloxi (palonosetron HCl). Albuquerque, NM: Cardinal Health, July 2003.

50.

50. Aapro

Bourke

JP.

Rapid intravenous administration of granisetron prior to chemotherapy is not arrhythmogenic: results of a pilot study. Eur J Cancer 2003;39:927–31.

51.

51. Carmichael

Harris

AL.

High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerability. Anticancer Drugs 2003;14:739–44.

52.

52. Carmichael

Harris

AL.

The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy. Cancer Chemother Pharmacol 2004;53:123–8.

53.

53. Navari

Koeller

JM.

Electrocardiographic and cardiovascular effects of 5–hydroxytryptamine₃ receptor antagonists. Ann Pharmacother 2003;37:1276–86. DOI 10.1345/aph.1C510.

54.

54. Schnell

Coop

AJ.

An evaluation of potential signals for ventricular arrhythmia and cardiac arrest with dolasetron and granisetron in the FDA combined Spontaneous Reporting System/Adverse Event Reporting System. Presented at: 8th International Conference on Geriatric Oncology: Cancer in the Elderly. Rome, November 21–22, 2003.

55.

55. Bloomer

Baldwin

Smith

Ayrton

Clarke

Chenery

RJ.

Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 1994;38:273–98.

56.

56. Dixon

Colthup

Serabjit-Singh

Kerr

Boehlert

Park

Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995;23:1225–30.

57.

57. Sanwald

David

Dow

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5–HT₃ antagonists. Drug Metab Dispos 1996;14:602–9.